Le navigateur que vous utilisez n’est pas pris en charge.
Il est possible que certaines fonctionnalités de ce site ne s’affichent pas correctement. Pour une expérience de navigation optimale, veuillez consulter ce site dans Chrome, Firefox, Safari ou Edge.

Image de la bannière avec molécule bleue et rouge

Congrès

Documents du congrès

Accéder aux résumés, posters et présentations présentés aux congrès suivants

Juin 2022

World Congress on Gastrointestinal Cancer (Congrès mondial sur le cancer gastrointestinal) (WCGI)

Juin 2022

Asian Oncology Society (AOS)

Juin 2022

European Hematology Association (Association européenne d’hématologie) (EHA)

European Hematology Association (Association européenne d’hématologie) (EHA)

June 2022 (Vienna, Austria)

Posters

A phase 1 first‑In‑human study of BGB‑16673, a Bruton tyrosine kinase protein degrader, in patients with B‑cell malignancies (trial in progress) A phase 1 study with the novel BCL2 Inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial Patient-reported outcomes from a phase 3 randomized study of zanubrutinib vs bendamustine plus rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme data set Preliminary safety and efficacy of BGB‑11417, a potent and selective B‑cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma Real-world treatment patterns and economic burden of patients with marginal zone lymphoma Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia Tislelizumab, a PD‑1 inhibitor for relapsed/refractory mature (NK)/T‑cell neoplasms: results from a phase 2 study Zanubrutinib in older patients with relapsed/refractory marginal zone lymphoma (MZL): subgroup analysis of the Magnolia study

Résumés

A phase 1 first in-human study of BGB-16673, a Bruton tyrosine kinase protein degrader, in patients (pts) with B-cell malignancies (trial in progress) A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with B-cell malignancies: preliminary data Efficacy of first-line treatment for chronic lymphocytic leukemia: a bayesian network meta-analysis Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia Patient-reported outcomes from a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) CLL/SLL Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML) Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma Real-world treatment patterns and economic burden of patients with marginal zone lymphoma Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia Treatment persistence and adherence to ibrutinib in patients with Waldenstrӧm macroglobulinemia: a German claims data analysis Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies Zanubrutinib in older patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): subgroup analysis of the MAGNOLIA study
Juin 2022

American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)

American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)

June 2022 (Chicago, Illinois, United States)

Résumés

A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM) ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM) AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC) Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208 Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208 Efficacy of first-line treatment for chronic lymphocytic leukemia: a Bayesian network meta-analysis Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC), RATIONALE 302: Asia subgroup Real world evidence of impact of atrial fibrillation (AF) on clinical and economic outcomes in patients with chronic lymphocytic leukemia (CLL) Real-world (RW) treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors (BTKi) in patients (pts) with mantle cell lymphoma (MCL) Real-world treatment (tx) patterns and economic burden of patients (pts) with marginal zone lymphoma (MZL) Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL) Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: results from a phase 2 study Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): preliminary results from a phase 1b/2 study Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: preliminary results from a phase 1b/2 study Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
Mai 2022

International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)

Mai 2022

International Conference on Clinical and Experimental Hematology (ICCEH)

Avril 2022

Transplantation & Cellular Therapy (TCT)

Avril 2022

American Society of Clinical Oncology Plenary Series Program (ASCO)

Avril 2022

American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)

American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)

Avril 2022 (Nouvelle Orléans, Louisiane, États-Unis)
Avril 2022

British Society for Haematology (Société britannique d’hématologie) (BSH)

MARS 2022

Italian Society of Experimental Hematology (Société italienne d’hématologie expérimentale) (SIES)

MARS 2022

Korean Society of Hematology (Société coréenne d'hématologie) (KSH)

MARS 2022

European Lung Cancer Congress (Congrès européen pour le cancer du poumon) (ELCC)

MARS 2022

French Society of Hematology (Société française d’hématologie) (SFH)

MARS 2022

Society of Gynecologic Oncology (Société d’oncologie gynécologique) (SGO)

MARS 2022

Francophone Days of Hepato-gastroenterology and Digestive Oncology (Journées francophones d’hépato-gastroentérologie et d’oncologie digestive) (JFHOD)

Francophone Days of Hepato-gastroenterology and Digestive Oncology (Journées francophones d’hépato-gastroentérologie et d’oncologie digestive) (JFHOD)

Mars 2022 (Paris, France)
MARS 2022

European Society of Medical Oncology Targeted Anticancer Therapies (Société européenne d’oncologie médicale, thérapies anticancéreuses ciblées) (ESMO-TAT)

Février 2022

Japanese Society of Medical Oncology (Société japonaise d’oncologie médicale) (JSMO)

Janvier 2022

British Thoracic Oncology Group (groupe d’oncologie thoracique britannique) (BTOG)

Janvier 2022

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)

Janvier 2022 (San Francisco, Californie, États-Unis)

Posters

AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 (PD-L1) AdvanTIG-206: anti-TIGIT monoclonal antibody ociperlimab + anti-PD-1 monoclonal antibody tislelizumab + BAT1706 vs tislelizumab + BAT1706 as first-line treatment for unresectable hepatocellular carcinoma Clinical outcomes associated with tislelizumab in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib or lenvatinib in RATIONALE-208 Clinical outcomes in patients with previously treated advanced hepatocellular carcinoma experiencing hepatitis B virus DNA increases during tislelizumab treatment in RATIONALE-208 DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life Updated analysis from a phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors

Résumés

AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1) AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 vs TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC) Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208 Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208 DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC) Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL) Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
Décembre 2021

American Society of Hematology (Société américaine d’hématologie) (ASH)

American Society of Hematology (Société américaine d’hématologie) (ASH)

Décembre 2021 (Atlanta, Géorgie, États-Unis)

Présentations

Factors associated with treatment among older adults diagnosed with chronic lymphocytic leukemia: an analysis using Medicare claims data Impact of atrial fibrillation on cardiovascular and economic outcomes in patients with chronic lymphocytic leukemia Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies Preliminary safety and efficacy data from patients with relapsed/refractory B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with zanubrutinib Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers Real-world Bruton tyrosine kinase inhibitor treatment patterns, compliance, costs, and hospitalizations in patients with mantle cell lymphoma in the United States Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: disparities and risk factors Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic lymphoma among veterans in the United States SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma Zanubrutinib in combination with venetoclax for patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p): early results from Arm D of the SEQUOIA (BGB-3111-304) trial

Résumés

Factors associated with treatment among older adults diagnosed with chronic lymphocytic leukemia: an analysis using Medicare claims data Impact of atrial fibrillation on cardiovascular and economic outcomes in patients with chronic lymphocytic leukemia Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients (pts) with relapsed/refractory B-cell malignancies Preliminary safety and efficacy data from patients (pts) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with zanubrutinib Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers Real-world Bruton tyrosine kinase inhibitor treatment patterns, compliance, costs, and hospitalizations in patients with mantle cell lymphoma in the United States Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenstrӧm macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: disparities and risk factors Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic lymphoma among veterans in the United States SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): early results from Arm D of the SEQUOIA (BGB-3111-304) trial
Décembre 2021

European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)

European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)

Décembre 2021 (Genève, Suisse)
Décembre 2021

Immunotherapy Bridge (IBC)

Novembre 2021

International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)

Novembre 2021

Australasian Melanoma Conference (Conférence australasienne sur le mélanome) (AMC)

Novembre 2021

Clinical Oncology Society of Australia (Société d’oncologie clinique d’Australie) (COSA)

Novembre 2021

Portuguese Society of Hematology (Société portugaise d’hématologie) (SPH)

Novembre 2021

Society for Immunotherapy of Cancer (Société d’immunothérapie pour le cancer) (SITC)

Octobre 2021

Italian Society of Hematology (Société italienne d’hématologie) (SIE)

Octobre 2021

Academy of Managed Care Pharmacy Nexus (Nexus Académie de gestion pharmaceutique des soins) (AMCP Nexus)

Octobre 2021

Spanish Society of Medical Oncology (Société espagnole d’oncologie médicale) (SEOM)

Octobre 2021

Spanish Society of Hematology and Hemotherapy (Société espagnole d’hématologie et d’hématothérapie) (SEHH)

Octobre 2021

Australasian Gastro-Intestinal Trials Group (Groupe australasien d’essais gastro-intestinaux) (AGITG)

Octobre 2021

German, Austrian, and Swiss Societies for Hematology & Medical Oncology (Sociétés allemandes, autrichiennes et suisses d’hématologie et d’oncologie médicale) (DGHO)

Septembre 2021

Society of Hematologic Oncology (Société d’oncologie hématologique) (SOHO)

Septembre 2021

Hematology Society of Australia and New Zealand (Blood) [Société d’hématologie d’Australie et de Nouvelle Zélande (sang)]

Hematology Society of Australia and New Zealand (Blood) [Société d’hématologie d’Australie et de Nouvelle Zélande (sang)]

Septembre 2021 (virtuel)
Septembre 2021

European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)

European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)

Septembre 2021 (virtuel)
Septembre 2021

International Workshop on CLL (Atelier international sur la leucémie lymphoïde chronique) (iwCLL)

Septembre 2021

Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)

Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)

Septembre 2021 (virtuel)

Résumés

A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors A phase II study of the efficacy and safety of tislelizumab plus lenvatinib in patients with advanced or metastatic hepatocellular carcinoma: results of safety run-in period First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study) Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 years Results from RATIONALE 303: a global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase 1b study Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC) Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study Zanidatamab (ZW25), a novel anti-HER2 bispecific antibody, monotherapy as second-line treatment for patients (pts) with advanced or metastatic HER2-amplified biliary tract cancer (BTC): a phase 2b trial-in-progress Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Septembre 2021

French Society of Hematology (Société française d’hématologie) (SFH)

Septembre 2021

World Congress on Lung Cancer (Congrès mondial sur le cancer du poumon) (WCLC)

Septembre 2021

Polish Society of Hematology and Transfusion Medicine (Société polonaise d’hématologie et de médecine transfusionnelle) (PTHiT)

Août 2021

Pan Pacific Lymphoma Conference (Conférence pan-Pacifique du lymphome) (PPLC)

Juillet 2021

International Symposium of Yonsei Song-dang Institute for Cancer Research (Symposium international de l’Institut Yonsei Song-dang de recherche sur le cancer) (N/A)

International Symposium of Yonsei Song-dang Institute for Cancer Research (Symposium international de l’Institut Yonsei Song-dang de recherche sur le cancer) (N/A)

Juillet 2021 (Séoul, Corée du Sud)
Juin 2021

World Congress on Gastrointestinal Cancer (Congrès mondial sur le cancer gastrointestinal) (WCGI)

Juin 2021

International Conference on Malignant Lymphoma (Conférence internationale sur le lymphome malin) (ICML)

Juin 2021

European Hematology Association (Association européenne d’hématologie) (EHA)

European Hematology Association (Association européenne d’hématologie) (EHA)

Juin 2021 (virtuel)
Juin 2021

American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)

American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)

Juin 2021 (virtuel)

Posters

A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors ADVANTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 (PD-L1) AdvanTIG-302: anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs pembrolizumab in programmed death ligand 1-selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer Efficacy and safety of zanubrutinib versus rituximab-based chemotherapy in Waldenstrӧm macroglobulinemia (WM): matching-adjusted indirect comparisons PARALLEL 303: phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line chemotherapy RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 The effects of tislelizumab treatment on the health-related quality of life of non−small cell lung cancer patients who progressed on a prior platinum-containing regimen Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: a phase 1B/2 trial-in-progress

Résumés

A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors AdvanTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1) AdvanTIG-302: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) vs pembrolizumab (PEM) in programmed death ligand 1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) Cardiac risk factors and adverse events among patients receiving first-line CLL treatment in a real-world community practice setting Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström macroglobulinemia (WM): matching-adjusted indirect comparisons PARALLEL 303: phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma RATIONALE-307: tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 Real-world treatment patterns, adherence, costs and healthcare resource utilization associated with Waldenström macroglobulinemia in the United States The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical hodgkin lymphoma (cHL): long-term follow-up efficacy and safety results from a phase 2 study Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: a phase 1B/2 trial-in-progress
Mai 2021

International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)

Avril 2021

American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)

Mars 2021

European Lung Cancer Congress (Congrès européen pour le cancer du poumon) (ELCC)

Mars 2021

Japanese Gastric Cancer Association (Association japonaise pour le cancer gastrique) (JGCA)

Japanese Gastric Cancer Association (Association japonaise pour le cancer gastrique) (JGCA)

Mars 2021 (virtuel)
Janvier 2021

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)

Décembre 2020

European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)

European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)

Décembre 2020 (virtuel)
Décembre 2020

American Society of Hematology (Société américaine d’hématologie) (ASH)

American Society of Hematology (Société américaine d’hématologie) (ASH)

Décembre 2020 (virtuel)
Novembre 2020

Society for Neuro - Oncology (Société de neuro-oncologie) (SNO)

Novembre 2020

International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)

Novembre 2020

Society for Immunotherapy of Cancer (Société d’immunothérapie pour le cancer) (SITC)

Society for Immunotherapy of Cancer (Société d’immunothérapie pour le cancer) (SITC)

Novembre 2020 (virtuel)
Octobre 2020

North America Conference on Lung Cancer (Conférence d’Amérique du Nord pour le cancer du poumon) (NACLC)

Septembre 2020

Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)

Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)

Septembre 2020 (virtuel)

Résumés

ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM) Neoadjuvant tislelizumab or placebo plus platinum-based chemotherapy followed by adjuvant tislelizumab or placebo in patients with resectable non‑small cell lung cancer (NSCLC): a phase 3 trial in progress Phase 3 trial in progress: tislelizumab plus cisplatin/carboplatin and gemcitabine versus placebo plus cisplatin/carboplatin and gemcitabine in Chinese patients with advanced urothelial carcinoma Phase 3 trial in progress: tislelizumab vs placebo in combination with concurrent chemoradiotherapy (cCRT) in patients with localized esophageal squamous cell carcinoma (ESCC) Platinum-containing combination chemotherapy with or without tislelizumab as first-line therapy in patients with extensive-stage small cell lung cancer: A phase 3 trial in progress RATIONALE 304: tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous non-small cell lung cancer (nsq-NSCLC) RATIONALE 307: phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone as first‑line (1L) treatment for advanced squamous non‑small cell lung cancer (sq NSCLC) Tislelizumab + chemotherapy versus placebo + chemotherapy in Chinese patients with recurrent or metastatic nasopharyngeal cancer: a phase 3 trial-in-progress Tislelizumab in Chinese patients with non-small cell lung cancer (NSCLC) Tislelizumab plus standard chemotherapy and health-related quality of life In patients with advanced squamous non-small cell lung cancer Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM) Zanubrutinib (BGB-3111) in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase 2, single-arm, multicenter, study
Septembre 2020

European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)

European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)

Septembre 2020 (virtuel)
Septembre 2020

Association of VA Hematology/Oncology (Association d’hématologie/oncologie VA) (AVAHO)

Juillet 2020

World Congress on Gastrointestinal Cancer (Congrès mondial sur le cancer gastrointestinal) (WCGI)

Juin 2020

American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)

Juin 2020

European Hematology Association (Association européenne d’hématologie) (EHA)

European Hematology Association (Association européenne d’hématologie) (EHA)

Juin 2020 (virtuel)
Mai 2020

American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)

American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)

Mai 2020 (virtuel)

Résumés

ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM) Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma BGB-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC) Phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL) Trial in progress: a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM) ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress. Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase II, single-arm, multicenter, study
Mai 2020

International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)

Février 2020

American Society of Clinical Oncology - Genitourinary Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers urogénitaux) (ASCO-GU)

Janvier 2020

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)

Décembre 2019

European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)

European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)

Décembre 2019 (Genève, Suisse)
Décembre 2019

American Society of Hematology (Société américaine d’hématologie) (ASH)

American Society of Hematology (Société américaine d’hématologie) (ASH)

Décembre 2019 (Orlando, Floride, États-Unis)

Résumés

A quantitative systems pharmacology (qsp) model to predict receptor occupancy of Bruton's tyrosine kinase (BTK) inhibitors in peripheral blood mononuclear cells, bone marrow and lymph nodes of patients with B-cell malignancies ALPINE: phase 3 trial of zanubrutinib (BGB-3111) vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) An update on safety and preliminary efficacy of highly specific Bruton tyrosine kinase (BTK) inhibitor zanubrutinib in combination with PD-1 inhibitor tislelizumab in patients with previously treated B-cell lymphoid malignancies BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): initial results from Arm C of the SEQUOIA (BGB-3111-304) trial Exposure-response relationship of the Bruton tyrosine kinase inhibitor, zanubrutinib (BGB-3111) in patients with hematologic malignancies Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma Randomized phase 2 zanubrutinib (BGB-3111) + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma (R/R FL) Treatment with the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrates high overall response rate and durable responses in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): updated results from a phase 1/2 trial
Novembre 2019

European Society for Medical Oncology-Asia (Société européenne d’oncologie médicale-Asie) (ESMO-Asie)

Novembre 2019

Society for Neuro - Oncology (Société de neuro-oncologie) (SNO)

Novembre 2019

International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)

International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)

Novembre 2019 (Copenhague, Danemark)
Septembre 2019

International Workshop on CLL (Atelier international sur la leucémie lymphoïde chronique) (iwCLL)

International Workshop on CLL (Atelier international sur la leucémie lymphoïde chronique) (iwCLL)

Septembre 2019 (Edinburgh, Écosse)
Septembre 2019

Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)

Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)

Septembre 2019 (Xiamen, Fugian, Chine)

Posters

A phase 2 trial in progress to evaluate the efficacy and safety of tislelizumab in Chinese patients with previously treated locally advanced unresctable or metastatic solid tumors with microsatellite instablity-high or mismatch repair deficiency A phase 3 trial In progress of platinum-containing combination chemotherapy with or without tislelizumab as first-line therapy in patients with untreated extensive-stage small cell lung cancer Dose escalation of pamiparib in Chinese patients with high-hrade non-mucinous ovarian cancer or advanced triple-negative breast cancer Pamiparib, an investigational PARP 1/2 inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA 1/2 mutations: an open-label, multicenter, phase 2 trial in China Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL) The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (FG/GEJ) adenocarcinoma: RATIONALE 305 Tislelizumab versus placebo in combination with concurrent chemoradiotherapy in patients with localized esophageal squamous cell carcinoma: a phase 3 trial in progress Zanubrutinib for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) Zanubrutinib, a highly specific BTK inhibitor in Chinese patients with relapsed/refractory B cell malignancies: follow up report of a phase 1 trial in China

Résumés

A phase 1B study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients (pts) with advanced solid tumors A phase 2 trial in progress to evaluate the efficacy and safety of tislelizumab in Chinese patients with previously treated locally advanced unresectable or metastatic solid tumors with microsatellite instability-high or mismatch repair deficiency A phase 3 trial in progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy in Chinese patients with recurrent or metastatic nasopharyngeal cancer Dose escalation of pamiparib in Chinese patients with high-grade non-mucinous ovarian cancer (HGOC) or advanced triple-negative breast cancer (TNBC) Pamiparib, an investigational PARP1/2 inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA 1/2 mutations: an open-label, multicenter, phase 2 trial in China Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL) Phase 3 study comparing tislelizumab in combination with cisplatin/carboplatin + gemcitabine with placebo in combination with cisplatin/carboplatin + gemcitabine as treatment for Chinese patients with advanced urothelial carcinoma: a trial in progress Phase 3 trial in progress of platinum-containing combination chemotherapy with or without tislelizumab as first-line therapy in patients with untreated extensive-stage small cell lung cancer (SCLC) RATIONALE 306: A randomized, placebo-controlled, double-blind trial in progress of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma Safety and efficacy in patients with long-term exposure (LTE) to tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human phase 1 study The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: updated follow-up efficacy and safety results from a phase 2 study Tislelizumab in Chinese patients (pts) with esophageal cancer (EC), gastric cancer (GC), hepatocellular carcinoma (HCC), and microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) tumors Tislelizumab in Chinese patients (pts) with non-small cell lung cancer (NSCLC) and nasopharyngeal carcinoma (NPC) Tislelizumab in Chinese patients with melanoma, urothelial carcinoma (UC), and renal cell carcinoma (RCC) Tislelizumab in combination with chemotherapy as treatment for Chinese patients with esophageal squamous cell carcinoma (ESCC) Tislelizumab plus chemotherapy as first-line treatment for Chinese patients with lung cancer Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: RATIONALE 305 Tislelizumab versus placebo in combination with concurrent chemoradiotherapy in patients with localized esophageal squamous cell carcinoma (ESCC): A phase 3 trial in progress Zanubrutinib for patients with relapsed or refractory chronic lymphocytic leukemia Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma Zanubrutinib, a highly specific BTK inhibitor in Chinese patients with relapsed/refractory B-cell malignancies: follow-up report of a phase 1 trial in China
Septembre 2019

World Congress on Lung Cancer (Congrès mondial sur le cancer du poumon) (WCLC)

Septembre 2019

European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)

European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)

Septembre 2019 (Barcelone, Espagne)
Juin 2019

International Conference on Malignant Lymphoma (Conférence internationale sur le lymphome malin) (ICML)

Juin 2019

European Hematology Association (Association européenne d’hématologie) (EHA)

Mai 2019

American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)

American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)

Mai 2019 (Chicago, Illinois, États-Unis)

Résumés

A phase 3 trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma A randomized, placebo-controlled, phase 3 trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC) ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Current treatment patterns and associated outcomes in Waldenström macroglobulinemia (WM) and related hematologic malignancies: a systematic literature review (SLR) Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL) Preliminary results with tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with nasopharyngeal cancer (NPC) Randomized phase 2 zanubrutinib (BGB-3111) + obinutuzumab (obi) vs obi monotherapy in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL) Tislelizumab, an investigational anti-PD-1 antibody, combined with chemotherapy as first-line treatment for lung cancer in Chinese patients
Mai 2019

International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)

International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)

Mai 2019 (Nouvelle Orléans, Louisiane, États-Unis)
Mars 2019

American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)

Février 2019

American Society of Clinical Oncology - Genitourinary Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers urogénitaux) (ASCO-GU)

Janvier 2019

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)

Décembre 2018

European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)

European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)

Décembre 2018 (Genève, Suisse)